NCT07813572Not yet recruitingPhase 3
ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular
A Phase 3, Randomized, Open-Label, Active-Controlled, Multicenter Study of ZG005 in Combination With Bevacizumab Versus Sintilimab in Combination With Bevacizumab in the First-Line Treatment of Advanced Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The purpose of the study is to evaluate the efficacy of ZG005 combined with bevacizumab compared with sintilimab combined with bevacizumab in the first-line treatment of participants with advanced HCC
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 600 (estimated)
- First submitted
- 4 Sept 2026
- Start date
- Sept 2026
- Primary completion date
- Sept 2031
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07813572
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 600
- From Sept 2026 to the primary completion date, Sept 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that is not suitable for participate in this study as determined by investigator.
Other
- Active Central nervous system (CNS) metastasis or leptomeningeal metastases.
Who the study is looking for
- Participants with histologically/cytologically confirmed unresectable or metastatic advanced HCC;
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
- Barcelona Clinic Liver Cancer stage B, not suitable for local treatment and BCLC C.
- At least one measurable lesion based on Recist1.1.
- No prior systemic therapy for HCC.
- Child-Pugh ≤6 , no history of hepatic encephalopathy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nanjing Tianyinshan Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.